Louis P. Kassa III, MPA, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), was awarded an honorary Doctor of Humane Letters at Holy Family University’s recent 2025 Graduate Commencement Ceremony.

Kassa also delivered keynote speeches at both the graduate and undergraduate ceremonies. A recording of the latter is posted here.

The university announcement stated that it had chosen to “recognize Kassa’s leadership in biotechnology, public service and education—fields that reflect Holy Family University’s commitment to innovation, community engagement and transformative learning.”

About the Hepatitis B Foundation: The Hepatitis B Foundation established the PABC in 2006 to be a home for its research institute and create a knowledge community that would accelerate the pace of research toward a cure for hepatitis B and liver cancer. As the world’s leading hepatitis B advocacy and research organization, the Foundation is one of the most active proponents of improving hepatitis B screening, prevention and treatment of the disease. We are the only nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with offices in Washington, D.C., and Philadelphia. To learn more, go to hepb.org, read our blog at hepb.org/blog, follow us on Twitter, Instagram and Facebook (@hepbfoundation) or call us at 215-489-4900.

About the Baruch S. Blumberg Institute:  An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is one of the nation’s leading centers for translational research in hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer in an environment conducive to interaction, collaboration and focus. For more, follow us on Twitter, @BlumbergInstit1, and LinkedIn.

About the Pennsylvania Biotechnology Center (PABC): Located in Doylestown and Philadelphia, Pa., in the heart of the Philadelphia-New Jersey pharma belt, the PABC is a nonprofit life sciences incubator-accelerator offering state-of-the-art laboratory and office space to nearly 70 early-stage biotech companies. The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries. To date, more than 75 companies have called PABC their home. PABC tenants account for 17% of all National Institutes of Health SBIR grants awarded in Pennsylvania and over the years have created billions of dollars in market value from IPOs, acquisitions and commercial valuations. For more information, please visit the PABC website, pabiotechbc.org and follow us on LinkedIn.